Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a late-stage biopharmaceutical company specializing in developing innovative antibiotics designed to combat drug-resistant bacterial infections. The company's leading drug candidate, ibezapolstat, is an orally administered antibiotic developed to treat Clostridioides difficile infections (CDI), a serious and life-threatening condition. Acurx is advancing ibezapolstat to Phase 3 clinical trials to establish its efficacy and safety compared to standard treatments such as vancomycin.
Ibezapolstat works by targeting the Gram-Positive Selective Spectrum (GPSS庐) and inhibiting the DNA polymerase IIIC enzyme critical for bacterial replication in Gram-positive bacteria. This mechanism not only effectively treats the infection but also preserves the healthy gut microbiome, thus reducing the likelihood of infection recurrence. Acurx鈥檚 studies have shown promising results, including a 96% clinical cure rate and excellent microbiome preservation, establishing non-inferiority to vancomycin.
The company has received multiple designations from the FDA, including Qualified Infectious Disease Product (QIDP) and Fast Track status, which highlight the urgent need for new antibiotics to treat CDI. These designations facilitate expedited development and review processes, enabling faster patient access to new treatments.
Recent progress includes the successful completion of a Phase 2b clinical trial, which demonstrated high clinical cure rates and no recurrence of infection in patients treated with ibezapolstat. The company has also reached critical milestones with regulatory agencies, including the FDA and EMA (European Medicines Agency), paving the way for international Phase 3 trials.
Acurx is committed to addressing the growing threat of antibiotic resistance. The company鈥檚 R&D pipeline includes additional antibiotics targeting other serious Gram-positive bacterial infections, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and drug-resistant Streptococcus pneumoniae.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced new findings from its Phase 2a trial of ibezapolstat for treating C. difficile infections (CDI), presented at the 9th International C. diff Conference on November 5, 2021. The trial highlighted complete eradication of C. difficile by day three and growth of healthy microbiota. Notably, ibezapolstat therapy increased secondary bile acids, suggesting reduced CDI recurrence risk compared to vancomycin. The upcoming Phase 2b trial will further evaluate pharmacokinetics and microbiome changes as Acurx looks to continue its positive trajectory in CDI treatment.
Acurx Pharmaceuticals (ACXP) announced the presentation of new microbiome data from its Phase 2a trial for C. difficile Infection (CDI) at the 9th Annual International C. diff Conference on November 5, 2021. The study demonstrated a 100% success rate in eliminating CDI infections with no recurrences. The trial, which was terminated early upon recommendation due to positive results, will proceed to Phase 2b, enrolling 64 additional patients. Acurx aims to further evaluate the effectiveness of ibezapolstat compared to vancomycin, focusing on treatment outcomes and microbiome changes.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced it will release its 2021 third quarter financial results on November 15, 2021, at 8:30 am ET. CEO David P. Luci and CFO Robert G. Shawah will host a conference call to discuss the results and provide a business update. Acurx is developing Ibezapolstat, a novel antibiotic targeting resistant bacterial infections, which has received FDA designations including Fast Track and Qualified Infectious Disease Product for its potential treatment of C. difficile. The company is preparing for a Phase 2b clinical trial.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced promising results for ibezapolstat in a Phase 2a clinical trial targeting Clostridioides difficile infections during the IDWeek 2021 conference. The trial highlighted a 100% eradication rate of C. difficile by day three and showed favorable microbiome effects compared to vancomycin, including growth of beneficial bacteria. The company is advancing to a Phase 2b trial this quarter to compare ibezapolstat with vancomycin, focusing on pharmacokinetics and microbiome changes.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced its participation in the A.G.P. Biotech and Specialty Pharma Conference on October 13, 2021. The event will feature one-on-one virtual investor meetings aimed at discussing the company's innovative antibiotic developments targeting difficult bacterial infections.
The company's pipeline includes candidates for treating Clostridioides difficile, MRSA, VRE, and drug-resistant Streptococcus pneumoniae. For more information, visit .
Acurx Pharmaceuticals (NASDAQ: ACXP) announced a scientific poster presentation at IDWeek 2021 focusing on its Phase 2a clinical trial of Ibezapolstat for Clostridioides difficile infection (CDI). The trial has shown 100% success in eliminating the infection without recurrence among 10 treated patients, leading to the early termination of the Phase 2a segment. A Phase 2b trial will further investigate Ibezapolstat against vancomycin in 64 patients. CDI is a significant healthcare issue, with annual U.S. infections approaching 600,000 and a mortality rate of about 9.3%.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced its upcoming inclusion in the Russell Microcap Index effective September 20, 2021. This inclusion is based on market-capitalization rankings and style attributes, lasting for one year. The company aims to develop a new class of antibiotics, with its lead candidate, ibezapolstat, targeting C. difficile infections. CEO David P. Luci highlighted that this recognition enhances the company's visibility among investors and reflects progress in their drug development objectives.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that David P. Luci, President & CEO, will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 7:00 A.M. ET. This conference will take place from September 13-15, 2021. Investors can access the live presentation via a webcast link provided in the press release. Acurx focuses on developing novel antibiotics for challenging infections, targeting Gram-positive bacteria such as Clostridioides difficile and MRSA.
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) reported its second quarter 2021 results, highlighting significant developments in its antibiotic research. The company received a $500,000 grant from Health Holland for collaboration on DNA pol IIIC inhibitors and filed a provisional patent for ibezapolstat aimed at treating C. difficile Infection (CDI). Financially, Acurx showed a net loss of $4.0 million for the quarter, up from $0.9 million the previous year, with increased administrative expenses of $3.9 million. As of June 30, 2021, the cash balance stood at $17.1 million.
Acurx Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative antibiotics, will have its President & CEO, David P. Luci, present at the Emerging Growth Conference on August 18, 2021, at 11:15 a.m. Eastern Time. This interactive online event aims to engage current stockholders and the investment community, allowing for potential Q&A. The conference will be webcast live and archived for 30 days on the company's website. Acurx is developing antibiotics targeting hard-to-treat infections, including MRSA and VRE.
FAQ
What is the current stock price of Acurx Pharmaceuticals (ACXP)?
What is the market cap of Acurx Pharmaceuticals (ACXP)?
What is Acurx Pharmaceuticals' lead drug candidate?
How does ibezapolstat work?
What are the clinical trial results for ibezapolstat?
Has ibezapolstat received any special designations?
What are the next steps for ibezapolstat?
What other infections is Acurx targeting?
What is the significance of ibezapolstat's effect on the microbiome?
What recent regulatory progress has Acurx made?
How does Acurx plan to market ibezapolstat internationally?
Where can I find more information about Acurx Pharmaceuticals?
